GENFIT : Corporate Presentation for Corporate Access and Biotech Showcase during JP Morgan Healthcare Conference - January 2023

Corporate Presentation

Corporate Access and Biotech Showcase during JP Morgan Healthcare Conference

January 8 - 12, 2023

Disclaimer & Looking Forward Statement

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY.

CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED BY THIRD-PARTY CONSULTANTS AND OTHER INDUSTRY SOURCES. WHILE GENFIT BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS BEEN OBTAINED ARE RELIABLE, GENFIT HAS NOT INDEPENDENTLY VERIFIED THE ASSUMPTIONS ON WHICH PROJECTIONS OF FUTURE TRENDS AND PERFORMANCE ARE BASED. IT MAKES NO GUARANTEE, EXPRESS OR IMPLIED, AS TO THE ACCURACY AND COMPLETENESS OF SUCH INFORMATION.

This presentation contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about GENFIT's corporate strategy and objectives, the potential sizes of the markets for primary biliary cholangitis (PBC), cholangiocarcinoma (CCA), acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE) and urea cycle disorder (UCD), potential market opportunities within these markets, GENFIT's development plans, expected regulatory approvals, including the ability to obtain accelerated pathways, and clinical timelines, as well as the outcome of the ELATIVE™ phase 3 trial of elafibranor in PBC. The use of certain words, including "believe, "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward- looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, and efficacy of our product candidates, the progress, timing and results of our ongoing and planned clinical trials, timing and outcomes of review and approvals by regulatory authorities of our drug and diagnostic candidates, the impact of the COVID-19 pandemic, the effects of the competitive landscape, inflation and fluctuations in exchange rates and market and general economic conditions, and the Company's continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the French Autorité des marches financiers ("AMF"), including those listed in Section 2 "Risks Factors and Internal Control " of the Company's 2021 Registration Document ("Document d'Enregistrement Universel") filed with the AMF on April 29, 2022, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF(www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Form 20-F document filed with the SEC on the same date, and subsequent filings and reports filed with the AMF or SEC, including the Half-Year Business and Financial Report at June 30, 2022 or otherwise made public, by the Company.

In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

2

About GENFIT

Mission & Expertise

Pipeline

Financials

• Late-stagebiopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs
• 20+ years of expertise from discovery phase to late-stage development
• Strong track record to develop long term collaboration: Ipsen, Genoscience Pharma, Labcorp, Terns Pharmaceuticals

Expanded pipeline of innovative assets, comprising 6 independent programs with diversified mechanisms of action in 6 key therapeutic areas, and 2 diagnostics programs:

• • 1 Phase III readout in 2023
  • 3 programs in Phase II in 2023
  • 2 preclinical programs
  • 2 diagnostic programs
• In 2021, IPSEN became one of GENFIT's largest shareholders, acquiring 8% of its share capital
• Cash position: €163.6M as of Sept 30, 2022

150+ employees

700+ patents & patents application

Fully committed in the continuous improvement

of our CSR & ESG Performance1

WE SUPPORT

Euronext & NASDAQ listed: GNFT

Based in Lille, Paris,

Zurich & Cambridge, MA

ELA: elafibranor, PBC: Primary Biliary Cholangitis, NTZ: nitazoxanide, ACLF: Acute on chronic liver failure, CCA: cholangiocarcinoma, UCD: Urea cycle disorder, OAD: Organic acidemia disorder, HE: Hepatic encephalopathy, NASH: Nonalcoholic steatohepatitis	3
1.Since 2021 GENFIT has been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.

A new GENFIT, following execution of the 2021-2022 strategic plan

Leveraging GENFIT's strengths and experience in liver diseases…

• • in Research
  • in Clinical development
  • in Regulatory affairs
  • in Pre-commercialization
• to address the high unmet medical needs in several liver indications

Liver-focus

4

Elafibranor as a Potential Treatment for PBC (1/3) - Positive Phase 2 data

Statistically significant treatment effects with both 80mg and 120mg doses on the primary end-point* of serum alkaline phosphatase (ALP) change from baseline

Change from baseline in ALP at week 121

ALP % Change vs. baseline1

(Mean+SD)

vs.baseline

(n=45,12W)

-

41

ALP % change

+3% adjusted

%

-52% vs pbo

-44% vs pbo

*Non-parametric randomization ANCOVA with baseline as covariate

*** P-value vs. placebo: <0.001

Elafibranor awarded Breakthrough Therapy designation by the FDA and Orphan Drug Designation by the FDA & EMA for PBC2

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA1

Jörn Schattenberget. al. | Journal of Hepatology. Feb. 2021

Note:* confirmed in mITT* set. mITT (All subjects w/ available baseline value and at least one post baseline value under treatment for ALP)=Placebo (N=15), Elafi branor 80mg (N=15), Elafibranor 120mg (N=14). Per Protocol Set = Placebo (N=14), Elafibranor 80mg (N=14), Elafibranor 120mg (N=13). ITT (intend to treat) = Placebo (N=15), Elafibranor 80mg (N=14), Elafibranor 120mg (N=15).

1. Schattenberg et al. J. of Hepatol. 2021, Vol. 74, Issue 6:1344-1354;2. GENFIT Corporate Press Release June 29, 2019 "GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC.".

Elafibranor is a competitive 2L candidate for PBC

Note: Indirect Comparison of Selected Biochemical Endpoint1. Both studies were add-on investigational therapy to UDCA or monotherapy in patients unable to

tolerate UDCA. 2L: Second-line.*Elafibranor - mITT: All subjects w/ available baseline value and at least one post baseline value under treatment for ALP. **These are estimations-based figures as reported data is based on actual change from Baseline n ALP (U/L) .Elafibranor is an investigational compound and has not been approved by any regulatory authority in any indication. Obeticholic acid is registered in US and EU under the trade name OCALIVA®, please refer to the approved PI and SmPC.

1. Data from referenced clinical trials; 2. Schattenberg et al. J. of Hepatol. 2021, Vol. 74, Issue 6:1344-1354;3. Nevens, et al. NEJM 2016, 375(7):631-43.

5